Background. To inform efforts to prevent antituberculosis drug resistance acquired during treatment, particularly multidrug-resistant (MDR) tuberculosis, we analyzed surveillance records from the US state with the highest morbidity.
and public health costs to contain an epidemic in the late 1980s exceeded US$1 billion [7] . Hospitalization costs alone for a single episode of extensively drug-resistant tuberculosis can exceed US$600 000 [8] .
There are several pathways to tuberculosis drug resistance. A patient with an initially drug-susceptible strain may acquire drug resistance during treatment because of inadequate drug regimens or poor treatment adherence [9] . Preexisting resistance may be amplified when a drug-resistant strain develops resistance to additional drugs. Resistant strains can also be transmitted from person to person, for instance in institutional settings [10] and in the community, despite the possibility of a fitness cost of resistance that could reduce transmissibility compared to susceptible strains [11] .
Drug resistance acquired during treatment is not well characterized. In previous studies, particularly in regions where drug susceptibility tests (DSTs) are not standard practice, a history of previous treatment for tuberculosis disease has commonly served as a proxy for acquired drug resistance (ADR) [12] . Analyses of laboratory-confirmed acquired resistance based on consecutive isolates are rare. The few published studies have been limited to small samples and geographic regions or institutions with limited generalizability [13, 14] . We report the findings of the first large population-based analysis of the magnitude and predictors of ADR in California, the state with the largest population and tuberculosis burden in the United States.
METHODS

Setting, Study Population, and Data Sources
We analyzed all tuberculosis cases reported to the California Department of Public Health tuberculosis registry from January 1994 through December 2006. The case report contains patient demographic characteristics, social and behavioral risk factors, diagnostic and clinical factors, and case management information, including DST results. The case reports were matched to the California Office of AIDS registry of persons with human immunodeficiency virus (HIV) infection.
Definitions and Inclusion Criteria
In the United States, DST for all culture-positive cases became required in 1993, in response to a rising incidence of drug resistance [15] . Isolates from culture-positive cases are routinely tested at the beginning of treatment ("initial" DST), and a subset of cases with poor clinical response or delays in Mycobacterium tuberculosis culture conversion are candidates for a follow-up test ("final" DST). The final isolate is defined as the last isolate for which susceptibility testing is performed, and must be collected at least 30 days after the initial isolate. DST results were reported as resistant if any level of resistance was detected, including resistance at low drug concentrations.
Analysis was limited to isoniazid and rifampicin resistance; "MDR" is defined as resistance to at least isoniazid and rifampicin. Results susceptible to isoniazid and rifampicin are denoted "susceptible," and those with resistance to one but not the other "monoresistant." Cases with acquired monoresistance were those with susceptible initial DST results and monoresistance (but not MDR) on final DST. Acquired MDR was defined as the change from susceptible or monoresistant on initial DST to MDR on final DST. We analyzed cases if they had a positive M. tuberculosis culture, had DST results for at least isoniazid and rifampicin, and began antituberculosis treatment, including individuals who acquired isoniazid and/or rifampicin resistance compared to their initial DST results together with individuals who did not change their initial DST; we excluded cases that were MDR on initial DST.
Statistical Analysis
We determined the frequency, estimated the crude risks, identified epidemiologic predictors, and identified temporal clusters and trends of each ADR outcome. The 5 outcome variables for the crude risk calculations were acquired (1) isoniazid monoresistance, (2) rifampicin monoresistance, (3) MDR following a susceptible isolate, (4) MDR following isoniazid monoresistance, and (5) MDR following rifampicin monoresistance. For the univariate and multivariate analyses of predictors of ADR, and the trend analysis, we considered (1) any acquired isoniazid resistance (including both mono-and multidrug resistance), (2) any acquired rifampicin resistance, and (3) any acquired MDR (regardless of initial DST result). The crude risks of ADR were estimated by dividing the number of individuals who acquired resistance to the drug(s) by the number of individuals who were initially susceptible. We computed exact 95% confidence intervals (CIs) for all crude risks.
To identify risk factors for ADR, we first tested univariate associations between demographic, clinical, and tuberculosis risk variables and the outcome variables, and calculated Haldane-Gart-Zweifel estimates of odds ratios and their 95% CIs. To identify independent risk factors for acquired isoniazid monoresistance, rifampicin monoresistance, and MDR, we conducted multiple regression. We included demographic variables (age, sex, a binary US vs foreign birth variable), clinical and laboratory variables (history of previous tuberculosis disease, extrapulmonary disease, positive acid-fast bacilli [AFB] smear, HIV infection), and a health system variable ( private sector tuberculosis care provider) in each model. We also included, a priori, an indicator variable for cavitary chest radiograph findings without directly observed therapy (DOT) throughout the course of treatment, as DOT is particularly important for patients with the high bacillary loads associated with cavitary pulmonary lesions (eg, potentially very infectious patients). Furthermore, we included initial rifampicin monoresistance when modeling acquired isoniazid resistance, initial isoniazid monoresistance when modeling acquired rifampicin resistance, and both when modeling acquired MDR. We excluded death during treatment from the multivariate model. Bias-reduced logistic regression was conducted whenever cells contained zero observations. We calculated P values using the Mantel-Haenszel χ 2 method or Fisher exact test, and considered P values <.05 to be statistically significant. We tested for temporal clustering of ADR using the maximum excess events test [16] and tested for monotone trends over time using linear regression (using a time series bootstrap with a fixed window of 3 years). All analyses were done using R for Macintosh, V2 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Between January 1994 and December 2006, 46 953 tuberculosis cases were reported to the California tuberculosis registry, of which 36 155 (77%) had a positive M. tuberculosis culture ( Figure 1 ). Nearly all culture-positive cases had initial DST results reported for isoniazid and rifampicin, and began antituberculosis drug therapy (34 227 [95%]). Of these, 502 (1.5%) were already diagnosed with MDR on initial DST and were excluded from further analysis. The remaining 33 725 comprised the study population for our estimates of crude risks of ADR. Final DST results were subsequently reported for 1792 (5.3%) of these patients, who comprised the study population for the analyses of risk factors for drug resistance acquired during treatment. Table 1 compares patients whose surveillance record contained only initial DST results to patients for whom final results were also reported. Patients with final DST results were more likely to be male and US-born, and to have infectious pulmonary disease ( positive AFB smear or cavitary chest radiograph), initial drug resistance, and risk factors for poor tuberculosis treatment outcomes (such as HIV infection and a history of substance abuse). Both groups were similar in the proportions of the outcomes of completion of and death during tuberculosis treatment.
The initial DST results of the 33 725 cases yielded 30 548 (91%) susceptible isolates, 3039 (9.0%) isolates with isoniazid monoresistance, and 138 (0.41%) with rifampicin monoresistance.
Of the 33 725, a total of 49 (0.15%) acquired MDR during treatment. These consisted of 16 that were initially susceptible, 27 initially isoniazid monoresistant, and 6 initially rifampicin monoresistant ( Figure 1 ). The crude risk of acquiring MDR tuberculosis ranged from 0.052% (95% CI, .030%-.085%) for patients with initial susceptible isolates, to 0.89% (95% CI, .59%-1.3%) for patients with initial isoniazid monoresistance, to 4.3% (95% CI, 1.6%-9.2%) for those with initial rifampicin monoresistance. Acquired isoniazid monoresistance occurred in 0.098% (95% CI, .067%-.14%) of cases with initial susceptible isolates, and rifampicin monoresistance in 0.069% (95% CI, .043%-.11%).
Univariate analysis revealed that patients with acquired isoniazid resistance were significantly more likely to have had initial rifampicin resistance (OR, 18.1; 95% CI, 6.42-51.1; P < .0001), HIV infection (OR, 3.05; 95% CI, 1.62-5.74; P < .001), and to die during treatment (OR, 2.35; 95% CI, 1.12-4.92; P = .024), compared to patients without acquired isoniazid resistance (Table 2 ). However, they were less likely to have received DOT throughout therapy (OR, 0.57; 95% CI, .32-.99; P = .046). Factors associated with acquired rifampicin resistance in the univariate analysis were death during treatment (OR, 14.3; 95% CI, 3.62-60.1; P < .0001), HIV infection (OR, 9.92; 95% CI, 5.91-16.7; P < .0001), initial resistance to isoniazid (OR, 6.68; 95% CI, 3.99-11.2; P < .0001), initial resistance to pyrazinamide (OR, 3.04; 95% CI, 1.04-8.89; P = .04), extrapulmonary disease (OR, 2.91; 95% CI, 1.71-4.94; P = .0001), Mexican origin (OR, 2.11; 95% CI, 1.27-3.50; P = .004) and younger age (OR, 0.97; 95% CI, .95-.99; P = .0002). Table 3 summarizes univariate analysis of acquired MDR, by initial resistance pattern. Among individuals with initially susceptible isolates, HIV infection (OR, 8.44; 95% CI, 3.12-22.8; P < .0001), death during treatment (OR, 3.79; 95% CI, 1.2-11.9; P = .02), extrapulmonary disease (OR, 3.15; 95% CI, 1.14-8.75; P = .03), and Mexican origin (OR, 3.0; 95% CI, 1.12-8.04; P = .03) were significantly associated with acquired MDR. In the group with initial isoniazid monoresistance, patients with acquired MDR were significantly more likely to die during treatment (OR, 14.3; 95% CI, 4.25-48.2; P < .0001) and to have HIV coinfection (OR, 4.19; 95% CI, 1.29-13.6; P = .017). Owing to small cell sizes, we did not estimate associations with acquired MDR for patients with initial rifampicin monoresistance. Any acquired MDR tuberculosis (regardless of initial DST result) was associated with death during treatment (OR, 5.34; 95% CI, 2.84-10.1; P < .0001) and HIV infection (OR, 4.26; 95% CI, 2.30-7.90; P < .0001).
In the multivariate analysis, independent predictors of acquired isoniazid resistance were initial rifampicin resistance (OR, 10.3; 95% CI, 2.82-37.7; P < .001) and HIV infection (OR, 3.36; 95% CI, 1.33-8.50; P = .01) ( Table 4 ). For acquired rifampicin resistance, we found significant associations with initial resistance to isoniazid (OR, 11.2; 95% CI, 5.2-24.4; P < .001), HIV infection (OR, 9.39; 95% CI, 3.76-23.4; P < .001), and cavitary disease in the absence of DOT throughout the treatment regimen (OR, 2.65; 95% CI, 1.09-6.46; P = .03). We also found an inverse relationship between age and acquired rifampicin resistance (OR, 0.96; 95% CI, .94-.98; P = .002). Acquired The mean annual proportions of tuberculosis cases with ADR were 0.19% for rifampicin and 0.17% for isoniazid, compared to 0.15% for MDR tuberculosis. All 3 outcomes decreased significantly over the course of the 13-year study period (isoniazid: P = .009; rifampicin: P = .011; MDR: P = .014).
DISCUSSION
We present the results of this large population-based study of the risk of ADR using consecutive drug susceptibility test results during the same tuberculosis treatment course. Our main finding is that isoniazid or rifampicin drug resistance at tuberculosis diagnosis, HIV infection, and cavitary tuberculosis disease in the absence of complete DOT were independent predictors of laboratory-confirmed acquired MDR. Patients who acquired MDR were also significantly more likely than other tuberculosis patients to die during treatment.
In a previous study of all MDR tuberculosis in California spanning a similar period, we reported that baseline resistance at the time of diagnosis was independently associated with a history of previous tuberculosis disease, positive AFB smear, Asian or Pacific Islander origin, recent immigration to the United States, and death during treatment [6] . Unlike in the present study of acquired resistance, HIV infection was not found to predict baseline MDR tuberculosis, suggesting that risk factors for acquired resistance are not necessarily the same risk factors for baseline resistance [17] .
Our finding that isoniazid resistance was a risk factor for subsequently acquiring rifampicin resistance corroborates evidence that the risk of acquiring further drug resistance in the presence of initial drug resistance (eg, amplification of isoniazid monoresistance to MDR) is higher than the risk of acquiring resistance in susceptible strains [18] [19] [20] [21] . Previous studies have also reported a significant association between HIV infection and antituberculosis drug resistance-attributed to malabsorption of rifampicin or to drug interactions with antiretroviral medications-as was demonstrated here [14, 22, 23] .
There was no statistically significant association between any demographic characteristic and ADR in the multivariate analysis. However, we identified a univariate association between Mexican origin and acquired rifampicin monoresistance, and MDR (when the initial DST was susceptible). While the link between pyrazinamide resistance characteristic of Mycobacterium bovis infection and Mexican origin of tuberculosis patients has been well characterized in the United States [24] , associations with other forms of drug resistance are less recognized. In previous analyses, the Asian population had disproportionately high rates of baseline isoniazid and/or rifampicin resistance, but Mexican origin has not been associated with elevated rates of resistance to these principal drugs [6, 15] . The majority of the Mexican-born patients in the current study with ADR also had HIV infection (data not shown), warranting further investigation of this vulnerable demographic group with tuberculosis-HIV coinfection.
Our study contributes new information on ADR regarding the intersection of cavitary disease and DOT. Even when there is an adequate drug regimen, the high bacillary loads in cavitary disease theoretically predispose a tuberculosis patient to the development of drug resistance because more drug resistant phenotypes exist in the bacillary population. Previous studies have found cross-sectional associations between cavitary disease and baseline multidrug resistance [25, 26] . Because the application of DOT in an observational study is influenced by knowledge of risk factors and public health practice patterns the impact of DOT on ADR should be assessed using a sufficiently powered randomized controlled trial-a prohibitively expensive endeavor because ADR is rare. Our data did not support the findings of a population-based study in San Francisco [27] that reported the same rate of ADR among patients on DOT compared to those on self-administered treatment. In contrast, in a population-based study of rifampicin monoresistance in New York in the early 1990s, infrequent application of DOT was found to be an independent risk factor for acquired rifampicin resistance [28] . Our findings provide new, large population-based evidence to support recommendations that DOT be prioritized for tuberculosis patients with cavitary disease. The statistically significant decline in ADR in California is encouraging, in light of a previous study in San Francisco that had detected increases during 1990-1994, compared to 1985-1989 [14] . It is likely that the decline identified in the current study is in large part driven by the decline in tuberculosis cases with HIV coinfection seen in California since the late 1990s [3] . However, the decline in ADR has occurred in the context of a relatively constant proportion of baseline MDR tuberculosis [6] and the observation that an increasing portion of MDR tuberculosis in California is nearly extensively drug resistant [8] . Since the study period ended, decreasing public health resources may have compromised the application of DOT and increased ADR, warranting ongoing measurement.
Because acquisition of drug resistance during therapy is rare in a setting of low tuberculosis incidence, the large sample size of our study provides an important advantage. However, there were several limitations. Because crude risks ignore risk factors, they may not be generalizable to other populations with different risk factor profiles. Furthermore, because DSTs require a positive culture, we excluded culture-negative cases (23% of all cases); any acquired resistance that may have occurred in culture-negative cases was not ascertained. Similarly, some culture-positive cases without a reported final DST may have had undetected ADR, rendering our estimates artificially low. However, we note that proportions of treatment completion and of death during treatment in the group without final DST results were statistically similar to those in the group with final DST results, lessening concerns about the substantial impact of unrecognized ADR. Additionally, repeat specimens for DST were indicated only when treatment complications such as delayed culture conversion were encountered. The vast majority of patients had no follow-up DST, because they were responding well to therapy and ADR was unlikely to have occurred. Overestimation of the associations between predictor and outcome variables are a possibility, if patients with certain characteristics (eg, HIV infection) had follow-up DSTs at higher proportions than others (ie, if the study group was biased toward persons with conditions predisposing them to having a follow-up DST). However, the strong association between HIV infection and ADR may not be completely explained by an intermediate relationship between HIV infection and having a repeat DST. Due to the incompleteness of genotyping data spanning the study period, we could not assess the strain concordance of consecutive isolates, and therefore could not measure the contribution of reinfection during treatment. However, findings in hightuberculosis-prevalence regions that serial isolates from the same patient tend to be genotypically concordant [29, 30] , suggest that we observed true acquisition of resistance and not reinfection. Acquired tuberculosis MDR persists at low levels in California. Although the crude risk of developing MDR tuberculosis disease when initially susceptible represents a small risk for an individual (0.052%), the increased cost and worse clinical outcomes render the prevention of acquired MDR a continuing priority. At a minimum, prevention of ADR may prevent outbreaks attributed to transmission of resistant strains [31] . A commitment to DOT throughout therapy for patients with cavitary disease-in addition to those for whom DOT is already recommended (eg, children and adolescents, residents of institutional settings, substance and excess alcohol users, those with a history of previous tuberculosis disease, and those with a drug-resistant isolate)-may help prevent the costly and dangerous acquisition of drug resistance. Potential savings from the prevention of ADR in these risk groups may be substantial, as an MDR case can on average cost >4 times as much as a drug-susceptible case [32, 33] .
Notes
